All data are based on the daily closing price as of November 22, 2024
m
Medy-Tox
086900.KQ
91.63 USD
0.64
+0.70%
Overview
Last close
91.63 usd
Market cap
615.35M usd
52 week high
230.88 usd
52 week low
88.31 usd
Target price
149.74 usd
Valuation
P/E
N/A
Forward P/E
19.7628
Price/Sales
3.5125
Price/Book Value
1.753
Enterprise Value
648.39M usd
EV/Revenue
3.766
EV/EBITDA
8.3291
Key financials
Revenue TTM
175.59M usd
Gross Profit TTM
89.88M usd
EBITDA TTM
26.87M usd
Earnings per Share
N/A usd
Dividend
3.14 usd
Total assets
613.94B usd
Net debt
N/A usd
About
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method. It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.